Chronic Hepatitis News

Researchers found that both donation and use of hepatitis C-positive livers has steadily increased over the last couple years due to a significant number of livers from younger individuals related to the rise of drug overdose-related deaths, according to a recently published study.

Gilead Sciences announced plans to launch authorized generic versions of Epclusa and Harvoni, according to a company press release.

Hepatitis B viral suppression had a sustainable, positive impact on patient-reported outcomes, according to results of a long-term follow-up study.

Results of a randomized control study showed the potential for hepatitis surface antigen loss and sustained virologic response in patients without cirrhosis and negative for HBV e-antigen after stopping long-term tenofovir disoproxil fumarate, according to recently published data.

A review of adults with chronic hepatitis B who had continuous medical coverage showed that the presence of extrahepatic comorbidities such as hypertension, cardiovascular disease and diabetes were among the primary risks for chronic kidney disease.

The global number of individuals infected with hepatitis D and positive for hepatitis B surface antigen was twofold higher than previous estimates among those without high-risk behaviors and even higher among people who inject drugs or partake in risky sexual behavior, according to a recently published systematic review.

Eiger BioPharmaceuticals received written guidance from the FDA for the “D-LIVR” phase 3 study of lonafarnib for patients with hepatitis D, according to a press release.

Regular monitoring of hepatitis B DNA during immunosuppression therapy in patients with occult HBV demonstrated a clear cut-off between those who were more likely to progress to active HBV and those who avoided reactivation, according to a recently published study.

Results of an international systematic review showed that patients and their families had a poor understanding about advanced liver disease, felt they needed more information about treatments and how to get practical and psychological support, and were unaware of the potential for palliative care.

Cepheid received the CE-IVD mark for the Xpert HCV VL Fingerstick, a molecular test designed to detect and quantify hepatitis C RNA levels from a fingerstick blood sample, according to a press release.